Table 6.
Correlation analysis of YAP1 promoter methylation with the clinical parameters in Indian breast cancer patients
| Characteristics | Cases (%) | Unmethylated (%) | Methylated (%) | p value |
|---|---|---|---|---|
| Age (years) | ||||
| ≤50 | 78 (56.93) | 21 (26.92) | 57 (73.08) | 0.571 |
| >50 | 59 (43.07) | 19 (32.20) | 40 (67.80) | |
| Age at menarche | ||||
| ≤12 | 26 (18.98) | 8 (30.77) | 18 (69.23) | 0.815 |
| >12 | 111 (81.02) | 32 (28.83) | 79 (71.17) | |
| Menopausal status | ||||
| Premenopausal | 40 (29.20) | 12 (30) | 28 (70) | 1 |
| Postmenopausal | 97 (70.80) | 28 (28.87) | 69 (71.13) | |
| Age at menopause | ||||
| ≤45 | 33 (34.02) | 12 (36.36) | 21 (63.64) | 0.249 |
| >45 | 64 (65.98) | 16 (25) | 48 (75) | |
| ER status | ||||
| Positive | 81 (59.12) | 27 (33.33) | 54 (66.67) | 0.252 |
| Negative | 56 (40.88) | 13 (23.21) | 43 (76.79) | |
| PR status | ||||
| Positive | 47 (34.31) | 12 (25.53) | 35 (74.47) | 0.556 |
| Negative | 90 (65.69) | 28 (31.11) | 62 (68.89) | |
| Her2 status | ||||
| Positive | 66 (48.18) | 18 (27.27) | 48 (72.73) | 0.708 |
| Negative | 71 (51.82) | 22 (30.99) | 49 (69.01) | |
| Molecular subtypes of breast cancer | ||||
| Luminal A | 46 (33.58) | 16 (34.78) | 30 (65.22) | 0.584 |
| Luminal B | 38 (27.74) | 12 (31.58) | 26 (68.42) | |
| Her2-enriched | 28 (20.44) | 6 (21.43) | 22 (78.57) | |
| TNBC | 25 (18.25) | 6 (24) | 19 (76) | |
| Tumor size | ||||
| ≤5 | 55 (40.15) | 15 (27.27) | 40 (72.73) | 0.707 |
| >5 | 82 (59.85) | 25 (30.49) | 57 (69.51) | |
| Lymph node status | ||||
| Positive | 99 (72.26) | 29 (29.29) | 70 (70.71) | 1 |
| Negative | 38 (27.74) | 11 (28.95) | 27 (71.05) | |
| Clinical stage | ||||
| I+II | 45(32.85) | 11 (24.44) | 34 (75.56) | 0.43 |
| III+IV | 92(67.15) | 29 (31.52) | 63 (68.48) | |
| Histological grade | ||||
| I+II | 95 (69.34) | 27 (28.42) | 68 (71.58) | 0.839 |
| III | 42 (30.66) | 13 (30.95) | 29 (69.05) | |
p value (Fisher’s Exact Test), Bonferroni significance level p ≤ 0.005